Striatal neuronal loss correlates with clinical motor impairment in Huntington's disease

Movement Disorders

Volumn 27, Issue 11, 2012, Pages 1379-1386

  Guo, Zhihong ^a   Rudow, Gay ^a   Pletnikova, Olga ^a   Codispoti, Kari Elise ^a   Orr, Brent A ^a   Crain, Barbara J ^a   Duan, Wenzhen ^a   Margolis, Russell L ^a   Rosenblatt, Adam ^a,b   Ross, Christopher A ^a   Troncoso, Juan C ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

DARPP 32; Medium spiny neurons; Putamen; Stereology; Subthalamic nucleus

Indexed keywords

PHOSPHOPROTEIN DARPP 32;

ADULT; AGED; ARTICLE; CELL LOSS; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; FEMALE; HUMAN; HUNTINGTON CHOREA; IMMUNOHISTOCHEMISTRY; MALE; MOTOR DYSFUNCTION; NERVE CELL; NEURITE; NEUROPATHOLOGY; NEUROPIL; PRIORITY JOURNAL; PUTAMEN; STAINING; SUBTHALAMIC NUCLEUS;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; AUTOPSY; CASE-CONTROL STUDIES; CELL DEATH; CELL SIZE; CORPUS STRIATUM; DISABILITY EVALUATION; DOPAMINE AND CAMP-REGULATED PHOSPHOPROTEIN 32; FEMALE; HUMANS; HUNTINGTON DISEASE; MALE; MIDDLE AGED; MOTOR ACTIVITY; NEURONS; PSYCHIATRIC STATUS RATING SCALES; STATISTICS AS TOPIC;

EID: 84866617053     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25159     Document Type: Article

References (40)

1. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993; 72: 971-983.
2. Eidelberg D, Surmeier DJ. Brain networks in Huntington disease. J Clin Invest 2011; 121: 484-492.
3. Ross CA, Tabrizi SJ. Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 2011; 10: 83-98.
4. Vonsattel JP, DiFiglia M. Huntington disease. J Neuropathol Exp Neurol 1998; 57: 369-384.
5. Walker FO. Huntington's disease. Lancet 2007; 369: 218-228.
6. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
7. Marder K, Zhao H, Myers RH, et al. Rate of functional decline in Huntington's disease. Huntington Study Group. Neurology 2000; 54: 452-458.
8. Margolis RL, Ross CA. Diagnosis of Huntington disease. Clin Chem 2003; 49: 1726-1732.
9. Rosenblatt A, Abbott MH, Gourley LM, et al. Predictors of neuropathological severity in 100 patients with Huntington's disease. Ann Neurol 2003; 54: 488-493.
10. Albin RL. Selective neurodegeneration in Huntington's disease. Ann Neurol 1995; 38: 835-836.
11. Lange KW, Javoy-Agid F, Agid Y, Jenner P, Marsden CD. Brain muscarinic cholinergic receptors in Huntington's disease. J Neurol 1992; 239: 103-104.
12. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP, Jr. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 1985; 44: 559-577.
13. Ferrante RJ, Beal MF, Kowall NW, Richardson EP, Jr., Martin JB. Sparing of acetylcholinesterase-containing striatal neurons in Huntington's disease. Brain Res 1987; 411: 162-166.
14. Myers RH, Vonsattel JP, Stevens TJ, et al. Clinical and neuropathologic assessment of severity in Huntington's disease. Neurology 1988; 38: 341-347.
15. DiProspero NA, Chen EY, Charles V, Plomann M, Kordower JH, Tagle DA. Early changes in Huntington's disease patient brains involve alterations in cytoskeletal and synaptic elements. J Neurocytol 2004; 33: 517-533.
16. Ouimet CC, Langley-Gullion KC, Greengard P. Quantitative immunocytochemistry of DARPP-32-expressing neurons in the rat caudatoputamen. Brain Res 1998; 808: 8-12.
17. Bolam JP, Somogyi P, Takagi H, Fodor I, Smith AD. Localization of substance P-like immunoreactivity in neurons and nerve terminals in the neostriatum of the rat: a correlated light and electron microscopic study. J Neurocytol 1983; 12: 325-344.
18. Harris GJ, Codori AM, Lewis RF, Schmidt E, Bedi A, Brandt J. Reduced basal ganglia blood flow and volume in pre-symptomatic, gene-tested persons at-risk for Huntington's disease. Brain 1999; 122: 1667-1678.
19. Comella CL, Shannon KM. Hemiballismus. Curr Treat Options Neurol 1999; 1: 1-5.
20. DeLong MR. Primate models of movement disorders of basal ganglia origin. Trends Neurosci 1990; 13: 281-285.
21. Lee MS, Marsden CD. Movement disorders following lesions of the thalamus or subthalamic region. Mov Disord 1994; 9: 493-507.
22. Vidakovic A, Dragasevic N, Kostic VS. Hemiballism: report of 25 cases. J Neurol Neurosurg Psychiatry 1994; 57: 945-949.
23. Rudnicki DD, Pletnikova O, Vonsattel JP, Ross CA, Margolis RL. A comparison of huntington disease and huntington disease-like 2 neuropathology. J Neuropathol Exp Neurol 2008; 67: 366-374.
24. Hamani C, Saint-Cyr JA, Fraser J, Kaplitt M, Lozano AM. The subthalamic nucleus in the context of movement disorders. Brain 2004; 127: 4-20.
25. Iacono D, Markesbery WR, Gross M, et al. The Nun study: clinically silent AD, neuronal hypertrophy, and linguistic skills in early life. Neurology 2009; 73: 665-673.
26. West MJ, Gundersen HJ. Unbiased stereological estimation of the number of neurons in the human hippocampus. J Comp Neurol 1990; 296: 1-22.
27. van den Bogaard S, Dumas E, van der Grond J, van Buchem M, Roos R. MRI biomarkers in Huntington's disease. Front Biosci (Elite Ed) 2012; 4: 1910-1925.
28. Weir DW, Sturrock A, Leavitt BR. Development of biomarkers for Huntington's disease. Lancet Neurol 2011; 10: 573-590.
29. Aylward EH, Nopoulos PC, Ross CA, et al. Longitudinal change in regional brain volumes in prodromal Huntington disease. J Neurol Neurosurg Psychiatry 2011; 82: 405-410.
30. Tabrizi SJ, Scahill RI, Durr A, et al. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol 2011; 10: 31-42.
31. Hobbs NZ, Barnes J, Frost C, et al. Onset and progression of pathologic atrophy in Huntington disease: a longitudinal MR imaging study. AJNR Am J Neuroradiol 2010; 31: 1036-1041.
32. Graveland GA, Williams RS, DiFiglia M. Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease. Science 1985; 227: 770-773.
33. Augood SJ, Faull RL, Love DR, Emson PC. Reduction in enkephalin and substance P messenger RNA in the striatum of early grade Huntington's disease: a detailed cellular in situ hybridization study. Neuroscience 1996; 72: 1023-1036.
34. Deng YP, Albin RL, Penney JB, Young AB, Anderson KD, Reiner A. Differential loss of striatal projection systems in Huntington's disease: a quantitative immunohistochemical study. J Chem Neuroanat 2004; 27: 143-164.
35. Reiner A, Albin RL, Anderson KD, D'Amato CJ, Penney JB, Young AB. Differential loss of striatal projection neurons in Huntington disease. Proc Natl Acad Sci U S A 1988; 85: 5733-5737.
36. Crossman AR, Mitchell IJ, Sambrook MA, Jackson A. Chorea and myoclonus in the monkey induced by gamma-aminobutyric acid antagonism in the lentiform complex. The site of drug action and a hypothesis for the neural mechanisms of chorea. Brain 1988; 111: 1211-1233.
37. Park SY, Kim HJ, Cho YJ, Cho JY, Hong KS. Recurrent hemichorea following a single infarction in the contralateral subthalamic nucleus. Mov Disord 2009; 24: 617-618.
38. Guridi J, Obeso JA. The subthalamic nucleus, hemiballismus, and Parkinson's disease: reappraisal of a neurosurgical dogma. Brain 2001; 124: 5-19.
39. Lozano AM. The subthalamic nucleus: myth and opportunities. Mov Disord 2001; 16: 183-184.
40. Lange H, Thorner G, Hopf A, Schroder KF. Morphometric studies of the neuropathological changes in choreatic diseases. J Neurol Sci 1976; 28: 401-425.